Gerald S Lipshutz

Gerald S. Lipshutz is a Professor of Surgery and holds multiple professorial appointments in Urology, Molecular and Medical Pharmacology, Psychiatry and Biobehavioral Sciences, and Medicine at the University of California, Los Angeles (UCLA) David Geffen School of Medicine. He serves as Department Vice Chair of Surgery and holds the prestigious Joan S. and Ralph N. Goldwyn Chair in Immunobiology and Transplantation Research. His academic career spans multiple disciplines within medicine, reflecting his interdisciplinary research approach.

Dr. Lipshutz's research primarily focuses on gene therapy approaches for inherited metabolic disorders, particularly arginase deficiency and carbamoyl phosphate synthetase deficiency. His work investigates the neurological manifestations of these disorders and develops viral vector-based therapeutic strategies. His laboratory employs animal models, stem cell platforms, and translational imaging techniques to understand disease mechanisms and evaluate treatment efficacy. A significant portion of his research examines how neonatal gene therapy can prevent or correct neurological damage associated with metabolic disorders.

Analysis of Dr. Lipshutz's recent publications (2022-2025) reveals a strong emphasis on translational gene therapy research, with particular attention to AAV vectors for metabolic disorders, neurological manifestations of inborn errors of metabolism, and translational imaging techniques to assess treatment outcomes. His work bridges basic science and clinical applications, with several publications addressing first-in-human trials and clinical implementation challenges. His research has increasingly incorporated multimodal approaches, combining gene therapy with metabolic and neurological assessments.

• Joan S. and Ralph N. Goldwyn Chair in Immunobiology and Transplantation Research

Dr. Lipshutz has served as Principal Investigator on numerous NIH-funded research projects, including multiple R01, R21, R03, and K08 grants from the National Institutes of Health. His research program has received continuous NIH support for over 15 years, with current funding focusing on elucidating the role of arginase isoforms in neuronal development, developing stem cell platforms for studying arginase deficiency, and creating gene replacement strategies for metabolic disorders. He has mentored numerous researchers and collaborated extensively across disciplines.

Dr. Lipshutz leads a research laboratory focused on developing gene and cell replacement therapies for metabolic disorders with neurological manifestations. His team employs a multidisciplinary approach combining molecular biology, neuroscience, and clinical research to address the challenges of treating inborn errors of metabolism. The laboratory collaborates with clinicians, biochemists, and imaging specialists to translate basic discoveries into potential therapeutic applications.